Activity Description
Antibody drug conjugates (ADCs) represent a newer class of oncology drugs associated with corneal toxicity. This activity summarizes a series of video discussions with optometrists and ophthalmologists about recognition and grading of pseudomicrocysts and other ocular adverse events (AEs), options for managing AEs, and communication strategies with patients and the oncology care team.
Accreditation Statements
Sponsored by
Axiom Ophthalmic, LLC is a COPE-Approved Administrator.
This activity, COPE Activity Number 133297, is accredited by COPE for continuing education for optometrists. This course is approved for 1 hour of CE.
Course # 105694-SD
Activity # 133297
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Release Date: 07-31-2026
Expiration Date: 07-30-2027
Target Audience
This accredited educational activity is designed for optometrists.
Grant Support Statement
This activity is supported by an unrestricted educational grant from AbbVie.
Faculty
Program Description
Life-saving cancer treatments shouldn't cost patients their vision. Antibody drug conjugates (ADCs) are among the most promising treatments in modern oncology, and they're increasingly linked to corneal toxicity that eye care providers are uniquely positioned to detect and manage.
As ADCs move into earlier lines of cancer treatment, the need for proactive ocular monitoring and cross-specialty collaboration has never been greater. This resource shines a light on three of the most common ADCs, the vision-related side effects to watch for, and the communication strategies that keep patients, oncologists, and eye care teams aligned — so that life-saving treatment doesn't come at the cost of lifelong vision.
Expert Faculty
Learning Objectives
Credit Designation
Credit Hours: 1.0